IDH1 and acute myeloid leukemia: On the other hand, ivosidenib, a single agent used against R/R IDH1-mutated AML (19), which has been newly-recognized as ineligible for standard chemotherapy against IDH1-mutated AML (135), showed a CR/CRi rate of 30.4% and 42.4%, respectively, and an ORR of 41.6% and 54.5%, respectively, with a median OS of 8.8 months and 12.6 months, respectively.